To provide new insights into the characterization of FLT3–ITD mutations and their ratio, and to evaluate the prognostic value of these mutations, we set out this systematic, retrospective chart review examining real-life outcomes (patient demographics, clinical characteristics, treatment patterns, and outcomes) in Spanish and Portuguese patients with AML from the Programa Español de Tratamientos en Hematología (PETHEMA) epidemiologic registry. The gene discussed is FLT3; the disease is acute myeloid leukemia.